Fruquintinib (BioDeep_00000016501)

   


代谢物信息卡片


Fruquintinib

化学式: C21H19N3O5 (393.13246440000006)
中文名称: 呋喹替尼
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1=C(C2=C(O1)C=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(=O)NC
InChI: InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25)

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

同义名列表

1 个代谢物同义名

Fruquintinib



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Xiaomin Ding, Yuan Liu, YaWen Zhang, Jinrong Liang, Qian Li, Haiyan Hu, Yan Zhou. Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study. Anti-cancer drugs. 2022 Dec; ?(?):. doi: 10.1097/cad.0000000000001482. [PMID: 36539356]
  • Shuai Liu, Lu Lu, Feng Pan, Chunsheng Yang, Jing Liang, Jinfeng Liu, Jian Wang, Rong Shen, Fu-Ze Xin, Nan Zhang. Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer. Oncology research. 2022 May; 29(1):25-31. doi: 10.3727/096504022x16427607626672. [PMID: 35063062]
  • Hanyi Zeng, Fanke Peng, Jiachen Wang, Ru Meng, Jun Zhang. Effects of Fruquintinib on the Pluripotency Maintenance and Differentiation Potential of Mouse Embryonic Stem Cells. Cellular reprogramming. 2021 06; 23(3):180-190. doi: 10.1089/cell.2020.0100. [PMID: 34077681]
  • Xiaojuan Liu, Aisong Guo, Yuanyuan Tu, Wendie Li, Lele Li, Wangrui Liu, Yuanyuan Ju, Yamei Zhou, Aimin Sang, Manhui Zhu. Fruquintinib inhibits VEGF/VEGFR2 axis of choroidal endothelial cells and M1-type macrophages to protect against mouse laser-induced choroidal neovascularization. Cell death & disease. 2020 11; 11(11):1016. doi: 10.1038/s41419-020-03222-1. [PMID: 33247124]
  • Hongjie Qian, Songhua Fan, Ke Li, Yang Sai, Weiguo Su, Qian Chen, Yun Liu, Tingting Li, Wei Wang, Jingying Jia, Chen Yu, Yanmei Liu. Effects of a High-fat Meal on the Pharmacokinetics of the VEGFR Inhibitor Fruquintinib: A Randomized Phase I Study in Healthy Subjects. Clinical therapeutics. 2019 08; 41(8):1537-1544. doi: 10.1016/j.clinthera.2019.05.014. [PMID: 31272709]
  • Yi-Bin Mei, Shun-Bin Luo, Ling-Yan Ye, Qiang Zhang, Jing Guo, Xiang-Jun Qiu, Sai-Li Xie. Validated UPLC-MS/MS method for quantification of fruquintinib in rat plasma and its application to pharmacokinetic study. Drug design, development and therapy. 2019; 13(?):2865-2871. doi: 10.2147/dddt.s199362. [PMID: 31616134]
  • Sufeng Zhou, Feng Shao, Zhaoqiang Xu, Lu Wang, Ke Jin, Lijun Xie, Juan Chen, Yun Liu, Hongwen Zhang, Ning Ou. A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers. Cancer chemotherapy and pharmacology. 2017 Sep; 80(3):563-573. doi: 10.1007/s00280-017-3394-6. [PMID: 28730290]
  • Yi Gu, Jian Wang, Ke Li, Li Zhang, Hongcan Ren, Lixia Guo, Yang Sai, Weihan Zhang, Weiguo Su. Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. Cancer chemotherapy and pharmacology. 2014 Jul; 74(1):95-115. doi: 10.1007/s00280-014-2471-3. [PMID: 24817647]